Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Oncol.

Sec. Molecular and Cellular Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1580951

Cellular Senescence in Colorectal Cancer: Its Occurrence, Effect and Therapy

Provisionally accepted
Yabing  LiangYabing Liang1Miao  WangMiao Wang1Xianjue  WangXianjue Wang1Zhiqing  YangZhiqing Yang1Shucheng  WangShucheng Wang2Fengyi  LiFengyi Li2Liya  SuLiya Su1*Ling  YangLing Yang1*
  • 1The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
  • 2Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region, China

The final, formatted version of the article will be published soon.

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. Although the use of small molecule drugs or targeted drugs has shown significant efficacy in the treatment of CRC, the drug resistance after treatment and the high recurrence and metastasis rate are the key obstacles affecting the success rate of treatment and survival of patients. Cellular senescence constitutes an important barrier to tumor progression. Senescent tumor cells and stromal cells are among the reasons for cancer treatment resistance. Different senescent programs can exert inhibitory or promotional effects on CRC. In serrated adenomas of colon, the senescence induced by intrinsic oncogenes serves as a threshold that precancerous lesions must traverse to develop into cancer. And the exposing of anti-cancer treatment, such as chemotherapy and radiotherapy, some cells also enter a senescent state, presenting a stable cell cycle arrest and senescence-associated secretory phenotype (SASP). SASP can activate immune surveillance but also contribute to the maintenance of cellular senescence microenvironment to help the CRC progression. Hence, in the pursuit of effective CRC treatment strategies, the issue of senescent cells is inevitable. By targeting features of senescent cells, such as upregulated anti-apoptotic signaling, altered metabolic signaling, and differential SASP secretion, depletion of senescent cells could be a promising strategy for the treatment of CRC. This review summarizes the endogenous and exogenous factors leading to cell senescence in CRC, as well as drug mechanisms, and focuses on the research progress of senescent tumors and stromal cells in CRC. Eventually, we discuss the strategies for CRC senescent cells after anti-cancer treatment to provide some theoretical basis and direction for retarding the malignant progression and recurrence of CRC.

Keywords: colorectal cancer, senescence, Therapy-induced senescence, senescence-associated secretory phenotype, Tumor Microenvironment, senolytics, therapy

Received: 24 Feb 2025; Accepted: 28 Jul 2025.

Copyright: © 2025 Liang, Wang, Wang, Yang, Wang, Li, Su and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Liya Su, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
Ling Yang, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.